JP2023528826A - Ｓａｒｓ関連コロナウイルスに対する中和抗体 - Google Patents

Ｓａｒｓ関連コロナウイルスに対する中和抗体 Download PDF

Info

Publication number
JP2023528826A
JP2023528826A JP2022573673A JP2022573673A JP2023528826A JP 2023528826 A JP2023528826 A JP 2023528826A JP 2022573673 A JP2022573673 A JP 2022573673A JP 2022573673 A JP2022573673 A JP 2022573673A JP 2023528826 A JP2023528826 A JP 2023528826A
Authority
JP
Japan
Prior art keywords
seq
amino acid
variable region
chain variable
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528826A5 (enExample
Inventor
シュテファン ベッカー
ヘニング グリュル
フロリアン クライン
クリストフ クレーア
マティアス ゼーナー
Original Assignee
ウニヴェルジテート・ツー・ケルン
フィリップス－ウニヴェルジテート マールブルク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルジテート・ツー・ケルン, フィリップス－ウニヴェルジテート マールブルク filed Critical ウニヴェルジテート・ツー・ケルン
Publication of JP2023528826A publication Critical patent/JP2023528826A/ja
Publication of JP2023528826A5 publication Critical patent/JP2023528826A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022573673A 2020-05-29 2021-05-28 Ｓａｒｓ関連コロナウイルスに対する中和抗体 Pending JP2023528826A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20177354 2020-05-29
EP20177354.6 2020-05-29
EP20182325.9 2020-06-25
EP20182325 2020-06-25
EP20213562 2020-12-11
EP20213562.0 2020-12-11
PCT/EP2021/064326 WO2021239935A1 (en) 2020-05-29 2021-05-28 Neutralizing antibodies against sars-related coronavirus

Publications (2)

Publication Number Publication Date
JP2023528826A true JP2023528826A (ja) 2023-07-06
JP2023528826A5 JP2023528826A5 (enExample) 2024-06-05

Family

ID=76250344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573673A Pending JP2023528826A (ja) 2020-05-29 2021-05-28 Ｓａｒｓ関連コロナウイルスに対する中和抗体

Country Status (6)

Country Link
US (1) US20210371503A1 (enExample)
EP (1) EP4157455A1 (enExample)
JP (1) JP2023528826A (enExample)
CA (1) CA3180556A1 (enExample)
TW (1) TW202210504A (enExample)
WO (1) WO2021239935A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
US20240383968A1 (en) * 2020-12-11 2024-11-21 Boehringer Ingelheim International Gmbh Formulation for multi-purpose application
AU2022221297A1 (en) * 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
US12496470B2 (en) * 2021-07-14 2025-12-16 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI RUI ET AL.: "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", NATURE, vol. vol. 584 (7819), JPN6025025878, 26 May 2020 (2020-05-26), pages 120 - 124, ISSN: 0005792914 *

Also Published As

Publication number Publication date
WO2021239935A9 (en) 2023-07-13
US20210371503A1 (en) 2021-12-02
TW202210504A (zh) 2022-03-16
EP4157455A1 (en) 2023-04-05
WO2021239935A1 (en) 2021-12-02
CA3180556A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP2023528826A (ja) Ｓａｒｓ関連コロナウイルスに対する中和抗体
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
JP6412107B2 (ja) Ｒｓｖｇタンパク質に結合するヒト抗体
JP7498714B2 (ja) Ｂ型肝炎ウイルスを中和する抗体およびその使用
KR20210075129A (ko) 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법
US20240059757A1 (en) Antibodies against sars-cov-2 and methods of using the same
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
CN114644708B (zh) 呼吸道合胞病毒特异性结合分子
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
CN116528897A (zh) 靶向SARS-CoV-2的抗原结合分子
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
WO2021218879A1 (zh) Sars-cov-2中和抗体及其制备和应用
US20220380441A1 (en) Antibody compositions and methods for treating hepatitis b virus infection
TW202144406A (zh) ＳＡＲＳ－ＣｏＶ－２抗體及其應用
WO2022051223A1 (en) Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
US20230227539A1 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
TW202440626A (zh) Sars-cov-2中和抗體
JP2024542793A (ja) Ｓａｒｓ関連コロナウイルスに対する中和抗体
EP4190810A1 (en) Neutralizing antibodies against sars-related coronavirus
JP2024533166A (ja) 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
US20220073594A1 (en) Anti-sars-cov-2 neutralizing antibodies
JP2024504167A (ja) Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2022127739A1 (zh) 特异性结合SARS-CoV-2的抗原结合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260210